How it works:
Everolimus inhibits the mTOR signalling pathway, essential for cancer cell growth, survival and proliferation. It blocks blood vessel formation in tumours (antiangiogenic effect) and suppresses malignant cell replication.
Recommended for:
Advanced or metastatic hormone receptor-positive, HER2-negative breast cancer
Renal cell carcinoma after failure of VEGF-targeted therapy
Progressive neuroendocrine tumours of pancreatic, gastrointestinal or pulmonary origin
Tuberous sclerosis-associated subependymal giant cell astrocytoma
Organ transplant recipients (as an immunosuppressive agent, per medical protocols)
Postmenopausal hormone-positive breast cancer
Renal cell carcinoma
Pancreatic and GI neuroendocrine tumours
Astrocytoma with tuberous sclerosis
Immunosuppression (select cases)
Take orally once daily at the same time, with or without food, with water. The dosage must be adjusted by the physician based on the patient’s condition, diagnosis, and concurrent medications.
Contraindications:
Hypersensitivity to everolimus or other mTOR inhibitors
Severe active infections
Pregnancy and breastfeeding
Severe hepatic impairment (dose-dependent)
Side Effects:
Mouth ulcers and stomatitis
Increased cholesterol and glucose levels
Infections due to immunosuppression
Skin rash and itching
Liver and kidney function disorders
Anaemia and thrombocytopenia
